When stratified by mutation profiles, patients with BRAF mutation or NRAS mutation NSCLC were more susceptible to metastasis (BRAF, 82.4% vs. 47.4%, P = 0.005; NRAS, 100% vs. 47.4%, P = 0.025). This evidence concerns the gene BRAF and non-small cell lung carcinoma.